Revenue missed consensus by a wide margin, driven by lower collaboration revenue. The EPS beat is not meaningful given the different share count and expense base. Monitor upcoming clinical data for STRO-004 and STRO-006 in H1/H2 2027 as key catalysts; the cash runway into H1 2028 provides a buffer but does not offset the revenue shortfall.
Drugs in focus
STRO drug pipeline →STRO-004
● Neutral Named in this press release- Impact
- Phase
- Phase 1
- Time to market
- Still in Phase 1 dose escalation; assuming successful Phase 1/2 and pivotal trials, potential approval would be several years away, likely 2029 or later.
- Next catalyst
- None dated
What to watchThe Phase 1 dose-escalation data from August 2026 showed early signals of activity (confirmed and unconfirmed partial responses) but also dose-limiting toxicities at the highest dose. The next update in H1 2027 will include expansion cohorts and more mature efficacy/safety data. Investors should watch for the dose selected for expansion, the durability of responses, and whether the safety profile supports a competitive advantage over the approved tissue-factor ADC Tivdak (tisotumab vedotin).
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $9.82entry
- T+1 · 20h ago −5.09%α −3.18% · $9.32
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Sutro Biopharma reported Q3 2026 revenue of $9.1M (below the $14.1M consensus) and GAAP EPS of -$1.90 (better than the -$1.96 consensus, but on a different share count basis). The company highlighted clinical progress for STRO-004 and STRO-006, a $10M milestone from Astellas, and a cash runway into H1 2028. Revenue missed consensus, while the EPS beat is largely a function of lower operating expenses and a higher share count.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $9.1M vs consensus $14.1M (miss)
- GAAP EPS -$1.90 vs consensus -$1.96 (beat on different basis; GAAP net loss $31.5M)
- Cash, cash equivalents and marketable securities $142.2M as of Sep 30, 2026
- Astellas dosed first patient in second dual-payload iADC program, triggering $10M milestone payment
- STRO-004 Phase 1 STRIVE-01 study advancing; next update and expansion cohorts expected H1 2027
- STRO-006 entered clinic with first patient dosed; initial update expected H2 2027
- STRO-227 advancing toward Phase 1 initiation in early 2027
- R&D and G&A expenses $31.0M vs $48.6M in prior year quarter
- Net loss per share improved to -$1.90 from -$6.66 due to lower expenses and higher share count
Financial Impact
Revenue miss of ~$5M vs consensus; cash burn of ~$22M in Q3; $10M milestone received from Astellas
Risk Factors
- Revenue miss vs consensus may pressure the stock near-term
- Clinical-stage biotech with no approved products; pipeline setbacks could materially impact valuation
- Cash burn rate; reliance on collaboration milestones for non-dilutive funding
- Deferred royalty obligation of $249M creates a significant liability
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402272 |
Track record
8 reports on STRO
1 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +50.74% at T+20 after the Mar 23, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 5/10 Viewing Entry $9.82 to $9.32 Now $9.32 +5.09% ▲ +5.09% +3.18% vs SPY
- Nov 9, 20267d ago SC 13G Neutral 3/10 Entry $10.61 to $10.17 Now $9.32 −12.16% ▼ −4.15% −3.78% vs SPY
- Aug 12, 202613w ago 8-K Bullish 7/10 No price data
- Aug 12, 202613w ago Press Release Mixed 6/10 Entry $21.30 to $21.31 Now $9.32 −56.24% ▲ +0.05% −0.65% vs SPY
- Apr 22, 202629w ago DEFA14A Neutral 3/10 Entry $34.83 to $33.33 Now $9.32 −73.24% ▼ −4.31% −5.09% vs SPY
- Apr 19, 202630w ago Press Release Bullish 7/10 Entry $34.58 to $34.35 Now $9.32 −73.05% ▼ −0.67% −0.01% vs SPY
- Mar 23, 202634w ago S-3 Bearish 6/10 Entry $23.57 to $23.50 Now $9.32 +60.46% ▲ +0.30% +0.86% vs SPY
- Mar 23, 202634w ago Press Release Bullish 7/10 Entry $23.57 to $23.50 Now $9.32 −60.46% ▼ −0.30% −0.86% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers